Alfapump (R) implantable device in management of refractory ascites: An update - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue World journal of hepatology Année : 2022

Alfapump (R) implantable device in management of refractory ascites: An update

(1) , (1) , , (1) , (2, 3) , (1)
1
2
3

Résumé

Refractory ascites (RA) is a frequent and life-threatening complication of cirrhosis. In selected patients with RA, transjugular intrahepatic portosystemic shunt (TIPS) placement and liver transplantation (LT) are currently considered the best therapeutic alternatives to repeated large volume paracentesis. In patients with a contraindication to TIPS or LT, the alfapump (R) system (Sequana Medical, Ghent, Belgium) has been developed to reduce the need for iterative. paracentesis, and consequently to improve the quality of life and nutritional status. We report here recent data on technical progress made since the first implantation, the efficacy and tolerance of the device, the position of the pump in the therapeutic arsenal for refractory ascites, and the grey areas that remain to be clarified regarding the optimal selection of patients who are potential candidates for this treatment.
Fichier non déposé

Dates et versions

hal-03778924 , version 1 (16-09-2022)

Identifiants

Citer

Delphine Weil-Verhoeven, Vincent Di Martino, Guido Stirnimann, Jean Paul Cervoni, Eric Nguyen-Khac, et al.. Alfapump (R) implantable device in management of refractory ascites: An update. World journal of hepatology, 2022, 14 (7), pp.1344-1356. ⟨10.4254/wjh.v14.i7.1344⟩. ⟨hal-03778924⟩

Collections

U-PICARDIE GRAP
14 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More